Status:
COMPLETED
Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
Lead Sponsor:
AstraZeneca
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18-99 years
Phase:
PHASE1
Brief Summary
A Phase I study to assess the safety and tolerability of AZD2281 in combination with Cisplatin in patients with advanced Solid Tumours. This is an open label-dose finding; to establish the maximum tol...
Eligibility Criteria
Inclusion
- Life expectancy of at least 12 weeks
- Histologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent
- Patients with measurable or non measurable disease according to RECIST
Exclusion
- Less than 28 days from active therapy (ie any treatment used to treat the disease) or high dose radiotherapy
- Brain Metastases or spinal cord compression unless irradiated at least 4 weeks before entry and stable without steroid treatment for \>1 week
- Persistent CTCAE Grade 2 or greater toxicities (excluding alopecia) caused by prior therapy
Key Trial Info
Start Date :
November 12 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 7 2023
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00782574
Start Date
November 12 2008
End Date
December 7 2023
Last Update
December 21 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Boston, Massachusetts, United States, 02114
2
Research Site
Boston, Massachusetts, United States, 02215
3
Research Site
Barcelona, Spain, 8035